National and Kapodistrian University of Athens
Μελέτη της HBV λοίμωξης και αναζωπύρωσης σε ασθενείς με ρευματικές παθήσεις υπό ανοσοκατασταλτική αγωγή
Abstract
dc:descriptionIntroduction: Hepatitis B Virus (HBV) is unique due to the complexity of the interaction between its viral replication and the host’s immune defense. In patients with rheumatic disease and chronic or resolved HBV infection who receive immunosuppressive therapy, HBV reactivation (HBVr) is a complication with potentially severe morbidity and mortality. In order to study the effect of biologic treatment in the course of HBV infection and the appearance of HBVr, we followed up a cohort of rheumatic patients with comorbid HBV infection and examined the kinetics of quantitative HBsAg (qHBsAg) in patient with chronic hepatitis B (CHB) or chronic HBV infection (CHI) as well as the kinetics of anti-HBs in patients with resolved HBV infection or immunization. Patients and Methods: In a single-center observational cohort study we identified patients with rheumatic diseases and comorbid HBV infection and studied hepatitis B epidemiology and the incidence of HBVr. HBsAg-positive rheumatic patients on biologic treatment (cases) were divided into two groups, depending on whether they suffered with CHB (group A) or CHI (group B) and were appropriately matched with non-rheumatic patients (controls) who were not receiving immunosuppressives. qHBsAg was measured in regular annual intervals and cases and controls were compared with regards to the changes in qHBsAg from baseline, the annual changes in qHBsAg, the probabilities of annual “rapid qHBsAg” (i.e. a drop in qHBsAg > 0.5 log10 iu/mL in any annual interval) and the rates of HBsAg loss. In patients with rheumatoid arthritis (RA) and evidence of resolved infection or immunization (anti-HBs-positive) who were receiving treatment with non-TNFi biologics, we compared anti-HBs serum titers at the start and the end of the treatment courses. Results:Among 852 patients with rheumatic disease who received at least one dose of biologic immunosuppressive therapy in our cohort, 38 (5.7%) had CHB or CHI, while evidence of resolved infection were identified in 119 (18%). 28 HBsAg-positive patients were divided in patients with CHB (group A, n=13) and patients with CHI (group B, n=15) and were matched to appropriate non-rheumatic controls. During their prospective follow up period (3.86 ± 2.8 years), none of the patients developed HBVr or hepatitis flare. For the patients in group A (CHB), there were no statistically significant differences in the change of qHBsAg from baseline or in the annual change between cases and controls. Similarly, the cumulative incidence of annual rapid qHBsAg decline (32.7% versus 28.4% at 4 years respectively, log-rank p = 0.726) and the probability of HBsAg loss (1/13 versus 2/26 at years respectively) did not differ significantly in survival analysis. On the contrary, in group B (CHI), the change in qHBsAg from baseline and the annual rates of qHBsAg decline were lower in rheumatic patients receiving immunosuppressive treatment and antiviral prophylaxis in comparison with non-rheumatic controls receiving no treatment. Furthermore, there was statistically significant difference in the cumulative incidence of annual rapid qHBsAg decline and HBsAg loss between cases and controls in survival analysis (0% and 0% versus 24% and 20% in 4 years, respectively). We also identified 36 rheumatoid arthritis patients with either resolved HBV infection (n=25) or immunization (n=11) who received 48 treatment courses with non-TNFi agents (female sex 89%, mean age 63.6 ±18 years, seropositive 58.3%) and had a mean follow up of 2.41 ±2 years. During follow up no cases of HBVr or biochemical hepatitis flare were identified, even though the anti-HBs titers dropped below 10 iu/mL in three patients. Serum anti-HBs titers were statistically significantly lower at the end of treatment courses (343 ±182 iu/mL) compared to their start (405 ±383 iu/mL) (p=0.004). With regards to different non-TNFi treatments, the change in anti-HBs titers was not significant for RTX and ABA, but the titers differed significantly for TCZ (start: 437 ±388 iu/mL versus end: 323 ±368 iu/mL, p=0.027).Conclusions:In patients with rheumatic disease on immunosuppressive treatment, the strategy of offering prophylactic antiviral therapy in patients with moderate/high risk for HBVr (HBsAg-positive) and careful monitoring in patients with low relevant risk (HBsAg-negative, anti-HBs-positive) was efficacious in preventing any cases of HBVr or hepatitis flares after a follow up of such patient in our cohort for approximately 4 and 2 years respectively. The annual qHBsAg decline, the annual rate of rapid qHBsAg decline and the probability of HBsAg loss were significantly lower in rheumatic patients with CHI, but not CHB, when compared to appropriate non-rheumatic controls. This may indicate that the combination of immunosuppressive treatment and antiviral prophylaxis that is recommended for those patients may alter the natural course of HBeAg-negative CHI and reduce the probability of “functional cure”. Finally, in patients with resolved HBV infection or immunization (anti-HBs-positive) and RA, treatment with non-TNFi agents caused small drops in anti-HBs titers between start and end of treatments which were not deemed clinically significant. Interestingly, between the non-TNFi agents, it was anti-IL6 inhibition with TCZ that correlated with the most pronounced drop in anti-HBs titers.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2021
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Koutsianas, Christos
- Κουτσιανάς, Χρήστος
Subjects
dc:subject × 18- HBV-ιός της ηπατίτιδας Β
- Ρευματικά νοσήματα
- Αντιγόνο επιφανείας του ιού της ηπατίτιδας Β
- Επανενεργοποίηση
- Ανοσοκατασταλτική θεραπεία
- Hepatitis B virus (HBV)
- Rheumatic diseases
- Hepatitis B surface antigen
- Reactivation
- Immunosuppression
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ρευματολογία
- Ηπατολογία
- Clinical Medicine
- Medical and Health Sciences
- Rheumatology
- Hepatology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/50819